Imlunestrant a next-generation oral SERD overcomes ESR1 mutant resistance in estrogen receptor–positive breast cancer is a research paper published in JCI Insight (2025). On theSindex it has a DataRank of 0.385. It has been cited 12 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.385
From this paper's citation signal
Citation Network Contribution
0
Citation network not refreshed for this result
This paper's DataRank is currently driven only by its base citation score. Citation network data was not refreshed for this result.
Learn more about DataRank methodology →Lilly
Grant: N/A
National Cancer Institute
Grant: R01CA237414
National Cancer Institute
Grant: R37CA279341
National Cancer Institute
Grant: 5 P30 CA06516
NCI NIH HHS
Grant: P30 CA006516
NCI NIH HHS
Grant: T32 CA236754
National Institutes of Health
Grant: 3P30CA006516-41S6
CANCER CENTER SUPPORT GRANT
National Institutes of Health
Grant: 1R01CA237414-01
CDK7 inhibitors as a new strategy to overcome treatment resistance in ER+ metastatic breast cancer
National Institutes of Health
Grant: 1R37CA279341-01
Structural-Transcriptional Relationships that Improve Y537S Estrogen Receptor Antagonism
FWCI
10.72
Citation Percentile
1.0%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals